Tempus AI Up 36% in Five Days — AI Healthcare Starts Talking Revenue

Tempus AI rose 15% on September 17th, bringing its five-session gain to roughly 36%. Management's guidance: two cancer diagnostic products are expected to contribute $80–100 million and $250–300 million in revenue respectively in 2027. The market's attention is shifting from the AI narrative toward a concrete commercialization path. Several industry catalysts landed over the same stretch. Novo Nordisk is partnering with Anthropic to accelerate drug development, ByteDance-spinoff AI pharma company Anew Labs closed a $290 million round, and the personalized cancer vaccine from Moderna and Merck met its Phase 3 endpoints. These three items sit at very different stages, though. Diagnostics already has a defined revenue model; AI drug discovery is still in the funding and validation phase; the cancer vaccine has to clear regulatory approval before it can be commercialized. Sectors tend to move together, but the actual timelines for delivery aren't on the same axis. Tempus's revenue guidance also points to 2027, with execution and payer coverage as two gates in between. Which thread looks more attractive to you — healthcare data, AI drug discovery, or cancer vaccines? Flexibly allocate across core U.S. tech equities and diversified RWA portfolios on Bitget — achieve efficient cross-asset allocation and precision risk hedging: https://www.bitget.com/promotion/futures-rwa